Inclusion Criteria:

          -  Be 20 years of age at the time the informed consent form is signed and of Japanese
             ethnicity (ie, both parents are native Japanese and were born in Japan).

          -  Have a solid tumor that has progressed on standard treatment:

               -  For patients enrolled in the dose-escalation portion, has confirmed solid tumor
                  that is locally recurrent or metastatic

               -  For patients enrolled in the dose-expansion portion, has high-grade serous
                  ovarian cancer, or BRCA 1/2 mutated breast cancer, or other solid tumor with BRCA
                  1/2 or related gene mutation

          -  Have to have evaluable disease (i.e. disease can be followed on scans.)

          -  Be willing and able to fast for at least 14 hours

        Exclusion Criteria:

          -  Active second malignancy

          -  Prior treatment with any PARP inhibitor

          -  Symptomatic and/or untreated CNS metastases

          -  Women who are breastfeeding or pregnant

          -  Pre-existing duodenal stent and/or any gastrointestinal disorder that would interfere
             with drug absorption

          -  Requires regular blood transfusions